LGK-974

For research use only. Not for use in humans.

目录号:S7143 别名: NVP-LGK974, WNT974

LGK-974 Chemical Structure

CAS No. 1243244-14-5

LGK-974 (NVP-LGK974, WNT974)是一种有效的特异性PORCN抑制剂,抑制Wnt信号通路,在TM3细胞中IC50为0.4 nM。Phase 1。

规格 价格 库存 购买数量  
10mM (1mL in DMSO) RMB 2022.93 现货
RMB 2019.87 现货
RMB 7962.02 现货
有超大折扣

今日订购,明日送达,全国免运费!

全国免费电话:400-668-6834   |   Email:info@selleck.cn

客户使用Selleck生产的LGK-974发表文献55篇:

产品安全说明书

PORCN抑制剂选择性比较

生物活性

产品描述 LGK-974 (NVP-LGK974, WNT974)是一种有效的特异性PORCN抑制剂,抑制Wnt信号通路,在TM3细胞中IC50为0.4 nM。Phase 1。
特性 LGK-974是口服有效的Porcupine-特异性抑制剂,用于治疗依赖Wnt配体的恶性肿瘤,目前处于I期临床试验阶段。
靶点
Porcn [1]
(TM3 cells)
体外研究

LGK-974在PORCN放射配体结合测定中,可有效取代[3H]GNF -1331,IC50为1 nM,在细胞中达到20µM时也没有很大的细胞毒作用。LGK974抑制所有测试的Wnts,IC50为0.05到2.4 nM,这与PORCN表型的基因缺失一致。[1] LGK974能特异性地抑制三种RNF43突变细胞株HPAF-II, PaTu 8988S, 和 Capan-2的生长。[2]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
HPAF-II  MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVmxJO69VcLi MYfEUXNQ M1XTXIlvcGmkaYTzJJRp\SCpcn;3eIghd2ZicHHuZ5Jm[XSrYzDjZY5k\XJiY3XscEBtcW6nczD3bZRpyqCUTl[0N412fGG2aX;uxsA> M{XoPVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ|OES3NlA{Lz5{M{i0O|IxOzxxYU6=
PaTu 8988S  MoGwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmLsNUDPxE4EoB?= NEjGS45FVVOR NHuxfGNqdmirYnn0d{B1cGViZ4Lve5RpKG:oIIDhcoNz\WG2aXOgZ4Fv[2W{IHPlcIwhdGmwZYOge4l1cMLiUl7GOFNufXSjdHnvcuKh MWC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzh2N{KwN{c,OjN6NEeyNFM9N2F-
Capan-2 NHHSbVJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MW[xJO69VcLi NVnjW2J{TE2VTx?= M3jPV4lvcGmkaYTzJJRp\SCpcn;3eIghd2ZicHHuZ5Jm[XSrYzDjZY5k\XJiY3XscEBtcW6nczD3bZRpyqCUTl[0N:KhdXW2YYTpc44> Mkn6QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN6NEeyNFMoRjJ|OES3NlA{RC:jPh?=
HPAF-II M2jWNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXexJO69VcLi MlfrSG1UVw>? MkPEbY5pcWKrdIOgeIhmKGe{b4f0bEBw\iCyYX7jdoVifGmlIHPhcoNmeiClZXzsJIxqdmW|IIfpeIjDqFKQRkSzxsBufXSjdHnvci=> MmO2QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN6NEeyNFMoRjJ|OES3NlA{RC:jPh?=
PaTu8988S NYjuNHV2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIXqU3IyKM7:TdMg MkLSSG1UVw>? MkLobY5pcWKrdIOgeIhmKGe{b4f0bEBw\iCyYX7jdoVifGmlIHPhcoNmeiClZXzsJIxqdmW|IIfpeIjDqFKQRkSzxsBufXSjdHnvci=> M{jxSlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ|OES3NlA{Lz5{M{i0O|IxOzxxYU6=
293T  NE\hdohHfW6ldHnvckBCe3OjeR?= M1zSR2lEPTEEoH;mJFAvPCCwTTD0c{BqdmirYnn0d{BYdnRic3nncoFtcW6pIHnuJJRp\SCjZn;y[Y1mdnSrb37l[EBYdnRiY3;jeYx1fXKnIHHzd4F6 MUO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDJ5N{i1OEc,OjR{N{e4OVQ9N2F-
293T  MkT0SpVv[3Srb36gRZN{[Xl? MUHJR|UxKG:oIEGgcm0hfG9iY3;tdIV1\SCxZn[gX|NJZS2JTl[tNVM{OSCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>? M3y1VlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2Mke3PFU1Lz5{NEK3O|g2PDxxYU6=
HT1080 NWf3S5NUTnWwY4Tpc44h[XO|YYm= Mnv4TY5pcWKrdHnvckBw\iCyb4LjeZBqdmViYXP0bZZqfHliKIXub45wf25ib4Lp[4lvMSCneIDy[ZN{\WRiaX6gbJVu[W5iSGSxNFgxKGOnbHzzJIF{e2W|c3XkJIF{KHO3cIDy[ZN{cW:wIH;mJHdvfDODLX3l[IlifGWmIIP1dIVzKHSxcDDmcIF{cCCjY4Tpeol1gSCkeTDTWGYhdHWlaX\ldoF{\SCjc4PhfUwhUUN3MDC9JFAvODByNDFOwG0v MmTLQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZ3MkK5OFYoRjJ4NUKyPVQ3RC:jPh?=
L Wnt3A, HEK293 MVzGeY5kfGmxbjDhd5NigQ>? NHPwXWs1QCCqcoO= MmPoTY5pcWKrdHnvckBw\iCZboSgd4lodmGuaX7nJEh2dmuwb4fuJI9zcWerbjmg[ZhxemW|c3XkJIlvKG2xdYPlJGwhX262M1GgZ4VtdHNiY3:tZ5VtfHW{ZXSge4l1cCCKRVuyPVMh[2WubIOgZYZ1\XJiNEigbJJ{KGK7IGP1dIVzNXSxcDDmcIF{cCC{ZYDvdpRmeiCpZX7lJIF{e2G7LDDJR|UxKD1iMD6wNFA6KM7:TT6= NYjlWYo6RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[2OFc{ODNpPkK2OlQ4OzB|PD;hQi=>
L Wnt3A, HEK293 NELYcohHfW6ldHnvckBie3OjeR?= M3XrVFQ5KGi{cx?= NUD1W25{UW6qaXLpeIlwdiCxZjDwc5JkfXCrbnWgbY4hdW:3c3WgUEBYdnR|QTDj[YxteyClbz3jeYx1fXKnZDD3bZRpKEiHS{K5N{Bk\WyuczDh[pRmeiB2ODDodpMh[nliU4Xw[ZIufG:yIH\sZZNpKHKncH;yeIVzKGenbnWgZZN{[XluIFnDOVAhRSByLkCwNFkh|ryPLh?= NH7kcmQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{N{[5NlUxQSd-Mke2PVI2ODl:L3G+
L Wnt3A, HEK293 NFW4N2dHfW6ldHnvckBie3OjeR?= M{XNWVQ5KGi{cx?= MU\Jcohq[mm2aX;uJI9nKHCxcnP1dIlv\SCrbjDtc5V{\SCOIGfueFNCKGOnbHzzJINwNWO3bIT1doVlKHerdHigTGVMOjl|IHPlcIx{KGG|c3Xzd4VlKGG|IIP1dJBz\XO|aX;uJI9nKFewdDDzbYdv[WyrbnegZYZ1\XJiNEigbJJ{KGK7IGP1dIVzNXSxcDDmcIF{cCC{ZYDvdpRmeiCpZX7lJIF{e2G7LDDJR|UxKD1iMD6wNFA6KM7:TT6= NUPBfJJ6RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0PVk1QDNpPkK5OFk6PDh|PD;hQi=>
HEK293T MUjGeY5kfGmxbjDhd5NigQ>? M4LVO|AvOSC3TR?= NFXJcoQ1QCCqcoO= MXfJcohq[mm2aX;uJI9nKHCxcnP1dIlv\SBqdX7rco94diCxcnnnbY4qKGmwIFjFT|I6O1RiY3XscJMhfHKjboPm[YN1\WRid3n0bEBxVGmkaX6tW25VO0FicHzhd41q\CCjc4Pld5Nm\CCjczDy[YR2[3Srb36gbY4hX262M1Ggd4VkemW2aX;uJIlvfG9iY3XscEBkfWy2dYLlJI1m\Gm3bTDheEAxNjFidV2gZYZ1\XJiNEigbJJ{KGK7IGfld5Rmem5iYnzveEB1\WOqbnnxeYU> NXjMb|ZIRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[2OFc{ODNpPkK2OlQ4OzB|PD;hQi=>
HEK293T MUfGeY5kfGmxbjDhd5NigQ>? NILGVIQxNjFidV2= NICxdHE1QCCqcoO= NXnSfXl2UW6qaXLpeIlwdiCxZjDwc5JkfXCrbnWgbY4hUEWNMkmzWEBk\WyuczD0doFve2[nY4Tl[EB4cXSqIIDMbYJqdi2ZTmSzRUBxdGG|bXnkJIF{e2W|c3XkJIF{KHKnZIXjeIlwdiCrbjDXcpQ{SSC|ZXPy[ZRqd25iaX70c{Bk\WyuIHP1cJR2emVibXXkbZVuKGG2IECuNUB2VSCjZoTldkA1QCCqcoOgZpkhX2W|dHXyckBjdG:2IH3leIhw\A>? NGm0XIE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{N{[5NlUxQSd-Mke2PVI2ODl:L3G+
BT-12 M2[xOpFJXFNiYYPzZZk> Mn24dWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[|ohWHKrbXHyfUB{[3KnZX6g[o9zKEKWLUGyJINmdGy| NV\NVHRvRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N|UyOzlpPkK5OFM2OTN7PD;hQi=>
NB1643 MUXxTHRUKGG|c3H5 MmLjdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[|ohWHKrbXHyfUB{[3KnZX6g[o9zKE6EMU[0N{Bk\Wyucx?= NWjpNIFrRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N|UyOzlpPkK5OFM2OTN7PD;hQi=>
OHS-50 M3vic5FJXFNiYYPzZZk> MkX6dWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[|ohWHKrbXHyfUB{[3KnZX6g[o9zKE:KUz21NEBk\Wyucx?= NF3PVow9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N|UyOzl:L3G+
SK-N-MC MUXxTHRUKGG|c3H5 NIT5SIpyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCScnntZZJ6KHOlcnXlckBnd3JiU1utUk1OSyClZXzsdy=> MXy8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR|NUGzPUc,Ojl2M{WxN|k9N2F-
HEK293 MoTDSpVv[3Srb36gZZN{[Xl? MYexNFAhdk1? NEDKZWU1QCCqcoO= MVrJcohq[mm2aX;uJI9nKHCxcnP1dIlv\SCrbjDISWszQTNiY3XscJMhfHKjboPm[YN1\WRid3n0bEBxVGmkaX6tW25VO0FicHzhd41q\CCjc4Pld5Nm\CCjczDkc5dvemWpdXzheIlwdiCxZjDMVnA3KHCqb4PwbI9zgWyjdHnvckBifCBzMECgcm0h[W[2ZYKgOFghcHK|IHL5JHdme3Sncn6gZoxwfCCjbnHsfZNqew>? MlrkQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2OUm0PFMoRjJ7NEm5OFg{RC:jPh?=
HEK293T NIPyNpdHfW6ldHnvckBie3OjeR?= M{Gye|ExOCCwTR?= M{LxfVQ5KGi{cx?= NXPud4M4UW6qaXLpeIlwdiCxZjDwc5JkfXCrbnWgbY4hUEWNMkmzWEBk\WyuczD0doFve2[nY4Tl[EB4cXSqIIDMbYJqdi2ZTmSzRUBxdGG|bXnkJIF{e2W|c3XkJIF{KHKnZIXjeIlwdiCrbjDXcpQ{SSC|ZXPy[ZRqd25iaX70c{Bk\WyuIHP1cJR2emVibXXkbZVuKGG2IEGwNEBvVSCjZoTldkA1QCCqcoOgZpkhX2W|dHXyckBjdG:2IH3leIhw\A>? NHvRdZk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUS5PVQ5Oyd-Mkm0PVk1QDN:L3G+
PA1 NVn1[JVxTnWwY4Tpc44h[XO|YYm= M2O5SlI1KGi{cx?= NGfC[4FKdmirYnn0bY9vKG:oIIDvdoN2eGmwZT3t[YRq[XSnZDDXcpQw[mW2YT3jZZRmdmmwIIPp[45idGmwZzDpckBpfW2jbjDQRVEh[2WubIOgZZN{\XO|ZXSgZZMh\G:5boLl[5Vt[XSrb36gc4YhSXirbkKgcXJPSSCneIDy[ZN{cW:wIHHmeIVzKDJ2IHjyd{BjgSC{ZXHsMZRqdWViUFPSJIFv[Wy7c3nz M1nCc|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEm5OFg{Lz5{OUS5PVQ5OzxxYU6=
HEK293 NVjtW41{TnWwY4Tpc44h[XO|YYm= NE\SOncyODBibl2= NYjydZBWPDhiaILz MoPoTY5pcWKrdHnvckBw\iCyb4LjeZBqdmViaX6gTGVMOjl|IHPlcIx{KHS{YX7z[oVkfGWmIIfpeIgheEyrYnnuMXdPXDODIIDsZZNucWRiYYPz[ZN{\WRiYYOg[I94dnKnZ4XsZZRqd25ib3[g[Il{cGW4ZXzl[EAzKHCqb4PwbI9zgWyjdHnvckBifCBzMECgcm0h[W[2ZYKgOFghcHK|IHL5JHdme3Sncn6gZoxwfCCjbnHsfZNqew>? MVW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR7OUS4N{c,Ojl2OUm0PFM9N2F-

... Click to View More Cell Line Experimental Data

Assay
Methods Test Index PMID
Western blot
Nrf2 / Wnt3A / HO-1 / NQO-1 / Survivin; 

PubMed: 28627706     


HepG2 cells were treated with LGK-974 at the indicated concentrations and collected after 24 h. Then, we extracted total protein samples for western blot analysis.

NF-κB / IκB / p-IκB; 

PubMed: 28128299     


BEAS-2B human bronchial epithelial cells were pretreated with 0.001–10 nM of LGK974 for 2 hours, followed by 0.1 μg/ml of LPS stimulation for 2 hours. Western blotting was used to assess protein levels and phosphorylation of NF-κB and IκB.

p-LRP6 / Axin / p-GSK3β / p-β-catenin / β-catenin; 

PubMed: 28128299     


BEAS-2B human bronchial epithelial cells were pretreated with 0.001–10 nM of LGK974 for 2 hours, followed by 0.1 μg/ml of LPS stimulation for 2 hours.

28627706 28128299
Immunofluorescence
α1, 6-fucosylation ; 

PubMed: 28798691     


Representative immunofluorescent and Lectin fluorescent images of α1, 6-fucosylation. (Scale bars = 50 μm; Magnification, 400×). 

FUT8; 

PubMed: 28798691     


Representative immunofluorescent and Lectin fluorescent images of FUT8 (Scale bars = 50 μm; Magnification, 400×). 

beta-catenin; 

PubMed: 25639201     


HTM cells treated with 10 μM KY02111 or LGK-974 likewise show a reduction of β-catenin staining intensity.

28798691 25639201
体内研究 LGK-974 (3 mg/kg)作用于小鼠MMTV-WNT1肿瘤模型和人的头部和颈部鳞状细胞癌模型(hn30),抑制 Wnt 信号通路,诱导肿瘤退化且小鼠体重没有明显的下降。[1] LGK-974 (5 mg/kg, p.o., BID) 也能抑制RNF43-突变胰腺肿瘤(HPAF-II 和Capan-2)的生长。[2]

推荐的实验操作(此推荐来自于公开的文献所以Selleck并不保证其有效性)

细胞实验:[2]
- 合并
  • Cell lines: HPAF-II, PaTu 8988S, 和 Capan-2 细胞
  • Concentrations: ~1 μM
  • Incubation Time: 3 天
  • Method: 细胞以每份密度6,000–12,000个接种在96孔板上,加入 DMSO或1 μM LGK974的培养基培养。3天后,加入新鲜的含有20 μM EdU的培养液,EdU来自Click-iT EdU Alexa Fluor 488 HCS试剂盒,孔板在37°C含有5% CO2的湿润空气温育2小时。用4% (mass/vol) paraformaldehyde固定细胞30分钟,用PBS清洗,渗透,然后用50 μg/mL溶于PBS的Hoechst 染色30分钟。清洗后,根据Click-iT EdU试剂盒的说明检测。在每种条件下每孔进行一式三份。
    (Only for Reference)
动物实验:[1]
- 合并
  • Animal Models: 小鼠MMTV-Wnt1肿瘤模型和人体头颈部鳞状细胞癌模型(HN30)
  • Dosages: ~3 mg/kg 每天
  • Administration: 口服灌胃
    (Only for Reference)

溶解度 (25°C)

体外 DMSO 79 mg/mL warmed (199.27 mM)
Water Insoluble
Ethanol Insoluble
体内 从左到右依次将纯溶剂加入产品,现配现用(数据来自Selleck实验检测而非文献):
2% DMSO+corn oil
5mg/mL

* 溶解度检测是由Selleck技术部门检测的,可能会和文献中提供的溶解度有所差异,这是由于生产工艺和批次不同产生的正常现象。请按照顺序依次加入各个纯溶剂。

化学数据

分子量 396.44
化学式

C23H20N6O

CAS号 1243244-14-5
储存条件 粉状
溶于溶剂
别名 NVP-LGK974, WNT974

动物体内配方计算器 (澄清溶液)

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
给药剂量 mg/kg 动物平均体重 g 每只动物给药体积 ul 动物数量
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系Selleck为您提供正确的澄清溶液配方)
% DMSO % % Tween 80 % ddH2O
计算重置

计算器

摩尔浓度计算器

摩尔浓度计算器

本计算器可帮助您计算出特定溶液中溶质的质量、溶液浓度和体积之间的关系,公式为:

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子量 (g/mol)

摩尔浓度计算公式

  • 质量
    浓度
    体积
    分子量

*在配置溶液时,请务必参考Selleck产品标签上、SDS / COA(可在Selleck的产品页面获得)批次特异的分子量使用本工具。

稀释计算器

稀释计算器

用本工具协助配置特定浓度的溶液,使用的计算公式为:

开始浓度 x 开始体积 = 最终浓度 x 最终体积

稀释公式

稀释公式一般简略地表示为: C1V1 = C2V2 ( 输入 输出 )

  • C1
    V1
    C2
    V2

在配置溶液时,请务必参考Selleck产品标签上、SDS / COA(可在Selleck的产品页面获得)批次特异的分子量使用本工具。.

连续稀释计算器方程

  • 连续稀释

  • 计算结果

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
分子量计算器

分子量计算器

通过输入化合物的化学式来计算其分子量:

总分子量:g/mol

注:化学分子式大小写敏感。C10H16N2O2 c10h16n2o2

摩尔浓度计算器

质量 浓度 体积 分子量
计算

临床试验信息

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT01351103 Recruiting Drug: LGK974|Biological: PDR001 Pancreatic Cancer|BRAF Mutant Colorectal Cancer|Melanoma|Triple Negative Breast Cancer|Head and Neck Squamous Cell Cancer|Cervical Squamous Cell Cancer|Esophageal Squamous Cell Cancer|Lung Squamous Cell Cancer Novartis Pharmaceuticals|Novartis December 1 2011 Phase 1

技术支持

在订购、运输、储存和使用我们的产品的任何阶段,您遇到的任何问题,均可以通过拨打我们的热线电话400-668-6834,或者技术支持邮箱tech@selleck.cn,直接联系到我们。我们会在24小时内尽快联系您。

操作手册

如果有其他问题,请给我们留言。

  • * 必填项

常见问题及建议解决方法

  • 问题 1:

    If LGK974 is a lipophilic or hydrophilic substance?

  • 回答:

    LGK974 is a lipophilic compound.

Tags: 购买LGK-974 | LGK-974供应商 | 采购LGK-974 | LGK-974价格 | LGK-974生产 | 订购LGK-974 | LGK-974代理商
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID